What are the latest updates to small-cell lung cancer (SCLC) treatment?

Latest Updates in Small Cell Lung Cancer Treatment

The most significant recent advances in SCLC treatment are the FDA approval of tarlatamab for relapsed disease and the establishment of consolidation durvalumab as standard of care for limited-stage SCLC after chemoradiotherapy. 1

Limited-Stage SCLC: Consolidation Immunotherapy

Patients with LS-SCLC who complete concurrent chemoradiotherapy without disease progression should receive consolidation durvalumab for up to 2 years. 1

Key Survival Benefits from ADRIATIC Trial:

• Median overall survival improved from 33.4 months (placebo) to 55.9 months (durvalumab) - representing a 22.5 month improvement 1
• 24-month OS rates: 68% vs 58.5% 1
• 36-month OS rates: 56.5% vs 47.6% 1
• Median PFS: 16.6 months vs 9.2 months (HR 0.76) 1

Practical Implementation:

• Start durvalumab 1,500 mg IV every 4 weeks within 1-42 days after completing chemoradiotherapy 1
• Continue for up to 2 years total 1
• Even patients with ECOG PS 3-4 may be offered durvalumab if their performance status improves after chemoradiotherapy 1

Safety Profile:

• Treatment-related grade 3-4 adverse events: 8.8% (durvalumab) vs 6% (placebo) 1
• Higher discontinuation rates (16.4% vs 10.6%) but manageable toxicity 1
• Immune-related AEs occurred in 32.1% vs 10.2% 1

Relapsed SCLC: Tarlatamab as New Standard Option

Tarlatamab, a DLL3-targeted bispecific T-cell engager, received FDA approval in May 2024 and now joins topotecan and lurbinectedin as preferred single-agent options for relapsed SCLC. 1

Efficacy Data from DeLLphi-301 Trial:

• Overall response rate: 40% with median duration of response of 9.7 months - substantially longer than other available agents 1
• Response rate in platinum-resistant disease: 52% 1
• Response rate in platinum-sensitive disease: 31% 1
• Median PFS: 4.9 months 1
• 9-month OS rate: 68% 1

Treatment Algorithm for Relapsed SCLC:

For chemotherapy-free interval <90 days (platinum-resistant):

• Preferred single agents: topotecan, lurbinectedin, or tarlatamab 1
• Single-agent therapy is preferred over multiagent regimens due to better risk-benefit balance 1

For chemotherapy-free interval ≥90 days (platinum-sensitive):

• Rechallenge with platinum-based regimen OR
• Single-agent therapy (topotecan, lurbinectedin, or tarlatamab) 1

Tarlatamab Dosing and Administration:

Step-up dosing regimen to mitigate toxicity: 1

• Cycle 1, Day 1: 1 mg IV
• Cycle 1, Day 8: 10 mg IV
• Cycle 1, Day 15: 10 mg IV
• Subsequent cycles: 10 mg IV every 2 weeks until progression or toxicity

Critical Safety Considerations:

Inpatient monitoring is mandatory for 24 hours after the first two doses (days 1 and 8 of cycle 1) to monitor for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). 1

CRS Profile: 1

• Occurred in 51% of patients (mostly grade 1-2)
• Grade 3 CRS: only 1%
• Median onset: 13 hours
• Median duration: 4 days
• Nearly all events during first cycle
• Symptoms: fever (97%), hypotension (20%), hypoxia (17%)

ICANS Profile: 1

• Occurred in 8% (all grade 1-2)
• Grade 3+ ICANS: 0%
• Median onset: 5 days

Exclusion criteria for tarlatamab: 1

• Interstitial lung disease
• Active pneumonitis
• Grade ≥2 pneumonitis from previous immunotherapy
• Severe immune-related adverse events from prior therapy

Patient Selection:

• Eligible after ≥2 prior systemic regimens (including platinum-based) 1
• ECOG PS 0-1 required 1
• Asymptomatic, previously treated, stable brain metastases allowed 1
• 73% of trial patients had prior immunotherapy 1

Extensive-Stage SCLC: First-Line Treatment Remains Unchanged

First-line therapy continues to be platinum-etoposide plus immunotherapy (atezolizumab or durvalumab) followed by maintenance immunotherapy. 1, 2

• Median OS with immunotherapy: 12-13 months 2
• Initial response rates: 60-70% 2
• However, 60% relapse within 3 months 2

Key Clinical Pearls and Pitfalls:

Sequencing uncertainty: There are currently no head-to-head trials comparing tarlatamab, lurbinectedin, and topotecan, so optimal sequencing remains unknown. 1 The ongoing DeLLphi-304 trial is comparing tarlatamab with standard chemotherapy to address this question. 1

Duration of response advantage: Cross-trial comparisons suggest tarlatamab's median duration of response (>9 months) is substantially longer than other agents, which may influence treatment selection despite lack of direct comparison data. 1

Durvalumab consolidation timing: The window for initiating durvalumab is 1-42 days after completing chemoradiotherapy - don't delay beyond this timeframe. 1

Performance status considerations: Even patients with poor PS (3-4) may benefit from durvalumab consolidation if their performance status improves after chemoradiotherapy, though this is a conditional recommendation with lower evidence quality. 1